New research indicates that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise plans.
Research printed in a prominent health publication shows that while obese individuals often shed substantial amounts of their body weight while on the medication, the mass returns at an average rate of 0.8 kg per month upon discontinuation.
"People buying these treatments must be cognizant of the potential of quick weight regain when the medication is stopped," warns lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a reversion to pre-treatment weight in about one and a half years.
Comparing Therapies
The research, which looked at dozens of studies involving over 9,000 of participants, compared the outcomes of GLP-1 agonists with older methods.
Researchers point out that individuals who lose weight through diet and exercise typically experience a less rapid creep back—perhaps 100 grams monthly—post-intervention.
Explaining the Rapid Rebound
Experts suggest the mechanism of the injections accounts for the amplified weight return.
These medications copy a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Long-term administration of the hormone levels far above than normal could lead to the system to generate a reduced amount of its endogenous hormone, and may also lessen sensitivity to its actions," said Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this GLP-1 'fix' leads to appetite is uncontrolled, making overeating far more likely."
A Chronic Issue?
Health authorities advise the injections for individuals with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
Professionals contend that, given the significant potential of weight regain, the treatment might need to be life-long.
This perspective is echoed by drug manufacturers, who note that the results "underscore the chronic character of obesity," akin to managing conditions like hypertension.
User Accounts
Individuals who have come off the jabs explain a sudden resurgence of cravings.
"It felt as if something that goes on and I was suddenly extremely hungry," said one woman.
This challenge is worsened if patients have not established permanent lifestyle or habit modifications during therapy.
Significant Adoption
Survey data suggest that millions of people in the UK have used these injections in the past year, with desire being substantial.
- Use is greater among women compared to men.
- The 40s and 50s age group shows the highest level of interest.
- Many obtain the drugs through private prescriptions rather than public health services.
Ultimately, clinicians emphasize that while the jabs are effective tools for weight loss, they are not a standalone fix and maintained weight loss hinges on integrated lifestyle changes.
